Literature DB >> 29298862

Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype.

Sandybell Anorga1, Jessica M Overstreet2, Lucas L Falke3, Jiaqi Tang1, Roel G Goldschmeding3, Paul J Higgins1, Rohan Samarakoon1.   

Abstract

Although yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), nuclear transducers of the Hippo pathway, are mostly silent in adult organs, aberrant activation of YAP/TAZ promotes tumorigenesis and abnormal tissue repair. The extent of involvement of TAZ in chronic kidney disease (CKD) is unknown. In our study, increased TAZ nuclear accumulation and expression in the tubulointerstitium was readily evident in 3 models of renal injury including obstructive, aristolochic acid (AA), and diabetic nephropathy, correlating with fibrosis progression. Stable TAZ overexpression in human kidney (HK)-2 epithelial cells promoted connective tissue growth factor (CTGF), fibronectin, vimentin, and p21 expression, epithelial dedifferentiation, and growth inhibition, in part, via Sma mothers against decapentaplegic homologue (SMAD)-3-dependent CTGF induction. CTGF secretion by TAZ-overexpressing epithelium also triggered proliferative defects in nonengineered HK-2 cells confirming a nonautonomous role of TAZ ( via a paracrine mechanism) in orchestrating kidney epithelial cell-cell communication. Renal tubular-specific induction of TGF-β1 in mice and TGF-β1 stimulation of HK-2 cells resulted in TAZ protein up-regulation. TAZ stable silencing in HK-2 cells abrogated TGF-β1-induced expression of target genes without affecting SMAD3 phosphorylation, which is also crucial for fibrotic reprogramming. Thus, TAZ was activated in fibrosis through TGF-β1-dependent mechanisms and sustained TAZ signaling promotes epithelial maladaptive repair. TAZ is also a novel non-SMAD downstream effector of renal TGF-β1 signaling, establishing TAZ as a new antifibrosis target for treatment of CKD.-Anorga, S., Overstreet, J. M., Falke, L. L., Tang, J., Goldschmeding, R. G., Higgins, P. J., Samarakoon, R. Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype.

Entities:  

Keywords:  AAN; CKD; CTGF; TGF-β1; UUO

Mesh:

Substances:

Year:  2018        PMID: 29298862      PMCID: PMC5901380          DOI: 10.1096/fj.201700722R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  48 in total

1.  Switch enhancers interpret TGF-β and Hippo signaling to control cell fate in human embryonic stem cells.

Authors:  Tobias A Beyer; Alexander Weiss; Yuliya Khomchuk; Kui Huang; Abiodun A Ogunjimi; Xaralabos Varelas; Jeffrey L Wrana
Journal:  Cell Rep       Date:  2013-12-12       Impact factor: 9.423

2.  TGF-β1 regulates the expression and transcriptional activity of TAZ protein via a Smad3-independent, myocardin-related transcription factor-mediated mechanism.

Authors:  Maria Zena Miranda; Janne Folke Bialik; Pam Speight; Qinghong Dan; Tony Yeung; Katalin Szászi; Stine F Pedersen; András Kapus
Journal:  J Biol Chem       Date:  2017-07-24       Impact factor: 5.157

Review 3.  TGF-β: the master regulator of fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2016-04-25       Impact factor: 28.314

4.  Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells.

Authors:  Robert Koesters; Brigitte Kaissling; Michel Lehir; Nicolas Picard; Franziska Theilig; Rolf Gebhardt; Adam B Glick; Brunhilde Hähnel; Hiltraud Hosser; Hermann-Josef Gröne; Wilhelm Kriz
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

Review 5.  Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis.

Authors:  Christiane Rüster; Gunter Wolf
Journal:  J Am Soc Nephrol       Date:  2011-06-30       Impact factor: 10.121

Review 6.  Renal fibrosis: novel insights into mechanisms and therapeutic targets.

Authors:  Peter Boor; Tammo Ostendorf; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2010-09-14       Impact factor: 28.314

7.  The contribution of chronic kidney disease to the global burden of major noncommunicable diseases.

Authors:  William G Couser; Giuseppe Remuzzi; Shanthi Mendis; Marcello Tonelli
Journal:  Kidney Int       Date:  2011-10-12       Impact factor: 10.612

Review 8.  Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy.

Authors:  Robert L Chevalier; Michael S Forbes; Barbara A Thornhill
Journal:  Kidney Int       Date:  2009-04-01       Impact factor: 10.612

Review 9.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer.

Authors:  Fa-Xing Yu; Bin Zhao; Kun-Liang Guan
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

Review 10.  Therapy for fibrotic diseases: nearing the starting line.

Authors:  Scott L Friedman; Dean Sheppard; Jeremy S Duffield; Shelia Violette
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

View more
  33 in total

1.  Nucleocytoplasmic Shuttling of the Mechanosensitive Transcription Factors MRTF and YAP /TAZ.

Authors:  Michael Kofler; András Kapus
Journal:  Methods Mol Biol       Date:  2021

Review 2.  The many talents of transforming growth factor-β in the kidney.

Authors:  Leslie Gewin
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-05       Impact factor: 2.894

3.  Rac-GTPase promotes fibrotic TGF-β1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways.

Authors:  Samik Patel; Jiaqi Tang; Jessica M Overstreet; Sandybell Anorga; Fei Lian; Alex Arnouk; Roel Goldschmeding; Paul J Higgins; Rohan Samarakoon
Journal:  FASEB J       Date:  2019-05-16       Impact factor: 5.191

4.  14-3-3ζ inhibits maladaptive repair in renal tubules by regulating YAP and reduces renal interstitial fibrosis.

Authors:  Tian-Tian Wang; Ling-Ling Wu; Jie Wu; Li-Sheng Zhang; Wan-Jun Shen; Ying-Hua Zhao; Jiao-Na Liu; Bo Fu; Xu Wang; Qing-Gang Li; Xue-Yuan Bai; Li-Qiang Wang; Xiang-Mei Chen
Journal:  Acta Pharmacol Sin       Date:  2022-07-15       Impact factor: 7.169

Review 5.  Emerging role of tumor suppressor p53 in acute and chronic kidney diseases.

Authors:  Jessica M Overstreet; Cody C Gifford; Jiaqi Tang; Paul J Higgins; Rohan Samarakoon
Journal:  Cell Mol Life Sci       Date:  2022-08-09       Impact factor: 9.207

6.  The signaling protein Wnt5a promotes TGFβ1-mediated macrophage polarization and kidney fibrosis by inducing the transcriptional regulators Yap/Taz.

Authors:  Ye Feng; Yan Liang; Xingwen Zhu; Mingjie Wang; Yuan Gui; Qingmiao Lu; Mengru Gu; Xian Xue; Xiaoli Sun; Weichun He; Junwei Yang; Randy L Johnson; Chunsun Dai
Journal:  J Biol Chem       Date:  2018-10-17       Impact factor: 5.157

Review 7.  TGF-β1-p53 cooperativity regulates a profibrotic genomic program in the kidney: molecular mechanisms and clinical implications.

Authors:  Craig E Higgins; Jiaqi Tang; Badar M Mian; Stephen P Higgins; Cody C Gifford; David J Conti; Kirstan K Meldrum; Rohan Samarakoon; Paul J Higgins
Journal:  FASEB J       Date:  2019-07-06       Impact factor: 5.834

8.  PAI-1 induction during kidney injury promotes fibrotic epithelial dysfunction via deregulation of klotho, p53, and TGF-β1-receptor signaling.

Authors:  Cody C Gifford; Fei Lian; Jiaqi Tang; Angelica Costello; Roel Goldschmeding; Rohan Samarakoon; Paul J Higgins
Journal:  FASEB J       Date:  2021-07       Impact factor: 5.191

Review 9.  MRTF: Basic Biology and Role in Kidney Disease.

Authors:  Maria Zena Miranda; Zsuzsanna Lichner; Katalin Szászi; András Kapus
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

Review 10.  The Genomic Response to TGF-β1 Dictates Failed Repair and Progression of Fibrotic Disease in the Obstructed Kidney.

Authors:  Craig E Higgins; Jiaqi Tang; Stephen P Higgins; Cody C Gifford; Badar M Mian; David M Jones; Wenzheng Zhang; Angelica Costello; David J Conti; Rohan Samarakoon; Paul J Higgins
Journal:  Front Cell Dev Biol       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.